The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers

Table 15

Percentage of DC subsets and expression of HLA-DR in the blood of women with LLABC undergoing NAC. Baseline (B) levels in LLABCs versus completion of chemotherapy (CC) levels in different responders.

Study group comparisons		mDC1	mDC1	pDC	pDC
			HLA-DR		HLA-DR
Good pathological responders (GPRs: )	B (%)	0.12 ± 0.04	36.07 ± 6.00	0.02 ± 0.02	50.86 ± 10.5
	CC (%)	0.10 ± 0.04	46.33 ± 8.00	0.05 ± 0.02	58.05 ± 12.00
	B versus CC; ( value)	NS	NS	NS	NS
	CC versus HFDs; ( value)	NS	NS	NS	NS
Poor pathological responders (PPRs: )	B (%)	0.08 ± 0.03	31.29 ± 6.00	0.02 ± 0.02	53.21 ± 10.00
	CC (%)	0.05 ± 0.03	29.83 ± 5.00	0.03 ± 0.02	49.97 ± 6.00
	B versus CC; ( value)	NS	NS	NS	NS
	CC versus HFDs; ( value)	0.048	0.001	0.017	0.023
Post-NAC GPR versus PPR	GPR CC versus PPR CC; ( value)	NS	0.041	NS	NS

LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; GPRs: complete or ≥90% reduction of tumour cell mass; PPRs: no or ≤90% reduction of tumour cell mass; HFDs: healthy female donors; NS: nonsignificant; statistically significant.